This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Abstract Details

Activity Number: 554
Type: Invited
Date/Time: Wednesday, August 4, 2010 : 2:00 PM to 3:50 PM
Sponsor: ENAR
Abstract - #306123
Title: The Role of Bayesian Statistics in Confirmatory Drug Development Trials
Author(s): David Ohlssen*+
Companies: Novartis Pharmaceuticals Corporation
Address: One Health Plaza, East Hanover, NJ, NJ 07936,
Keywords: Bayesian analysis ; missing data ; sensitivity analysis ; phase III trials ; historical data ; futility rules

In phase III, due to regulatory requirements on type one error control, there is a perception that Bayesian statistics has a limited role. Here, by considering a number of examples, we question this view. Firstly, as the vast majority of phase III trials employ single imputations to handling missing data, it is unclear that the desired type I error control is achieved. To improve, a principled approach based on modeling and sensitivity analysis is required. As Bayesian approaches are well suited to this, they perhaps should become an important partner in phase III statistical analysis. Secondly, we consider an example where a Bayesian futility rule was applied in a phase III study. Finally, more controversial designs will be discussed, where historical data is used to form a prior for one arm. When the control treatment is well established, this type of design could make sense.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2010 program

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.